2024.09.26OMEICOS, a portfolio company of Remiges Ventures, completes enrollment of PMD-OPTION study in primary mitochondrial disease

2024.09.10LUCA Science, a portfolio company of Remiges Ventures, has published significant research findings in Nature Metabolism: The study highlights how mitochondria transfer-based therapies can reduce morbidity and mortality in Leigh syndrome

2024.05.10ENB Therapeutics, one of Remiges Ventures’ portfolio companies, announced clinical collaboration between Coherus and the Cancer Research Institutes using ENB-003 for the treatment of ovarian cancer

2024.04.30InFlectis BioScience, a portfolio company of Remiges Ventures in France, was awarded a grant from the National Multiple Sclerosis Society to advance IFB-048 preclinical development in multiple sclerosis. The research will be performed by Prof. Brian Popko of Northwestern University

2024.03.04Glycomine, one of Remiges Ventures’ portfolio companies, announced encouraging efficacy data from ongoing Phase2 clinical study in PMM2-CDG

　　News　＞　

What Remiges Does >

Team >

Portfolio Companies >

Contact >

LP Portal >